Recent news on Daptomycin

Novartis says Swiss regulator approves antibiotic Daptomycin  -  May 2, 2007
MarketWatchWednesday said the Swiss drug regulator has approved Daptomycin for use in hospitalized patients with complicated skin and soft-tissue infections.

Astellas Pharma: telavancin enters EU battle for MRSA market share  -  May 2, 2007
Pharmaceutical Business Review...(linezolid) first launched in the EU in 2001 (and is already exhibiting resistance, but available orally), Cubist and Novartis’ Cubicin (daptomycin,

Cubist Pharmaceuticals to Present at May Conferences  -  Apr 25, 2007
Genetic Engineering News (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Daptomycin Is Clinically More Rapidly Effective Than Comparator ...  -  Apr 5, 2007
DG NewsMUNICH, GERMANY -- April 5, 2007 -- The cyclic lipopeptide antibiotic daptomycin elicits statistically significant earlier responses than vancomycin or

Cubist Pharmaceuticals to Present at May Conferences  -  Apr 25, 2007
Business Wire (press release),In the US, Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Cubist Pharmaceuticals Reports First Quarter 2007 Results: Total ...  -  Apr 18, 2007
Genetic Engineering News (press release),Net sales of CUBICIN(R) (daptomycin for injection) increased 57% from the prior year, from $37.9 million in the first quarter of 2006 to $59.4 million in

GSK meet no resistance for new antibacterial  -  Apr 16, 2007
DrugResearcher.com,In recent months, new antibiotics from the likes of Wyeth (Tygacil; tigecycline) Pfizer (Zyvox; linezolid) and Novartis/Cubist (Cubicin; daptomycin) have

Cubist Pharmaceuticals to Announce First Quarter 2007 Financial ...  -  Apr 6, 2007
American Digital Networks (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Targanta Reports Improved Ability Of Oritavancin To Stop Bacteria ...  -  Apr 4, 2007
Medical News Today (press release),Researchers tested the in vivo activity of ORI against penicillin- sensitive S. pneumoniae (PSSP) pneumonia in a mouse model, compared with daptomycin (DAP)

Targanta Reports Improved Ability of Oritavancin to Stop Bacteria ...  -  Apr 3, 2007
PR Newswire (press release),...activity of ORI against penicillin- sensitive S. pneumoniae (PSSP) pneumonia in a mouse model, compared with daptomycin (DAP) and ceftriaxone (CTX).

Antibacterials: narrow-spectrum strategy could change market  -  Mar 29, 2007
Pharmaceutical Business Review...agents - such as Wyeth's Tigecycline and Cubist/Novartis' Daptomycin - a widespread adoption of narrow spectrum policies, similar to the Royal Free's,

From soil in Haiti, hopes for antibiotic  -  Feb 9, 2007
Boston Globe,One of the substances, daptomycin , was licensed to Cubist in 1997 and eventually became Cubicin. Another drug, oritavancin, was licensed in 2001 to a

Cubist Pharmaceuticals to Present at February Investor Conferences  -  Feb 1, 2007
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Cubist Pharmaceuticals Announces Fourth Quarter 2006 US Net ...  -  Jan 8, 2007
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

Can anything stop the superbug?  -  Jan 17, 2007
Guardian Unlimited,What are needed now are new classes of antibiotics, and there have been only two in recent times - Wyeth's linezolid, licensed in 2001, and daptomycin from

Market Report -- In Play (CBST)  -  Jan 8, 2007
MSN Money...$59.68 mln Co announces Q4 US net product revs of $56.2 mln vs. consensus of $59.68 mln for its antibiotic product CUBICIN (daptomycin for injection).

Cubist Pharmaceuticals Announces Fourth Quarter 2006 US Net ...  -  Jan 8, 2007
Business Wire (press release),US net product revenues of $56.2 million (unaudited) for the fourth quarter of 2006 for its antibiotic product CUBICIN ® (daptomycin for injection).

AstraZeneca Licenses Rights for the Development and ...  -  Dec 5, 2006
PipelineReview.com (press release),Inc. for the development and commercialisation of the antibiotic CUBICIN® (daptomycin for injection) in China and certain other countries in Asia,

(China) AstraZeneca licenses rights for the development and ...  -  Dec 4, 2006
Biotecheast.com,CUBICIN (daptomycin for injection), is the first antibiotic in a new class of antiinfectives called lipopeptides. CUBICIN is currently the only once-daily

Cubist Pharmaceuticals Licenses Rights for Development and ...  -  Dec 4, 2006
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

AstraZeneca licenses rights to Cubist's Cubicin in China  -  Dec 5, 2006
Pharma Times (subscription),...agreement with the USA's Cubist Pharmaceuticals to develop and commercialise the latter's novel injectable antibiotic Cubicin (daptomycin) in China.

Anti-infective antibodies: finding the path forward  -  Dec 5, 2006
Nature.com (subscription),Novartis is considering administering AuroGrab along with its intravenous antibiotic daptomycin, and thus each drug could be used to boost sales of the

Cubist Pharmaceuticals to Present at November Investor Conferences  Nov 6, 2006
In the US, Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... -Business Wire (press release), Many Diagnostics (eg, Phenotypic Tests, Molecular Tests) Are Now ...  Nov 7, 2006
...use of current drugs? Will it increase or decrease use of drugs such as daptomycin, linezolid, and tigecycline? -- Impact of drug ... -Genetic Engineering News (press release), IDSA: MRSA Linked To Necrotizing Fasciitis  Oct 12, 2006
Luckily, he said, a range of agents is available, ranging from the newer drugs such as Cubicin (daptomycin) and Tygacil (tygecycline), as well as old standbys ... -MedPage Today, Source: The Nasdaq Stock Market, Inc.  Oct 24, 2006
In the US, Cubist markets CUBICIN(r) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... -PrimeZone (press release), Cubist Pharmaceuticals to Present at September Investor ...  Aug 30, 2006
In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... -PharmaLive.com

Daptomycin Knocks Out Most Infections in Dialysis Patients ...  -  Nov 20, 2006
DG NewsSAN DIEGO, CA -- November 20, 2006 -- The antibiotic agent daptomycin achieved a response in 85% of dialysis patients who were diagnosed with staphylococci

AstraZeneca Licenses Rights for the Development and ...  -  Dec 5, 2006
PipelineReview.com (press release),Inc. for the development and commercialisation of the antibiotic CUBICIN® (daptomycin for injection) in China and certain other countries in Asia,

(China) AstraZeneca licenses rights for the development and ...  -  Dec 4, 2006
Biotecheast.com,CUBICIN (daptomycin for injection), is the first antibiotic in a new class of antiinfectives called lipopeptides. CUBICIN is currently the only once-daily

Cubist Pharmaceuticals Licenses Rights for Development and ...  -  Dec 4, 2006
PharmaLive.com (press release),In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides.

AstraZeneca licenses rights to Cubist's Cubicin in China  -  Dec 5, 2006
Pharma Times (subscription),...agreement with the USA's Cubist Pharmaceuticals to develop and commercialise the latter's novel injectable antibiotic Cubicin (daptomycin) in China.

Anti-infective antibodies: finding the path forward  -  Dec 5, 2006
Nature.com (subscription),Novartis is considering administering AuroGrab along with its intravenous antibiotic daptomycin, and thus each drug could be used to boost sales of the

Daptomycin not inferior to standard therapy for S aureus ...  Aug 16, 2006
Durham, NC - Daptomycin (Cubicin, Cubist Pharmaceuticals), a cyclic lipopeptide antibiotic approved for the treatment of skin and skin-structure infections, is ... -TheHeart.Org

Daptomycin versus Standard Therapy for Bacteremia and Endocarditis ...  Aug 16, 2006
Methods We randomly assigned 124 patients with S. aureus bacteremia with or without endocarditis to receive 6 mg of daptomycin intravenously per kilogram of ... -New England Journal of Medicine (subscription)

Researchers show efficacy of first Staph drug for decades  Aug 22, 2006
The FDA has approved the drug, Daptomycin, in 2003 for treating S. aureus-related skin infections. In this latest study, the research ... -DrugResearcher.com

Dangerous Staph Infections: New Treatment Demonstrated  Aug 22, 2006
Based on the trial, the Food and Drug Administration already has approved the drug -- daptomycin -- for treating heart infections and bacteremia, also known as ... -Medical News Today

FDA APPROVES MRSA-BEATING DRUG  Aug 24, 2006
The US Food and Drug Administration have approved the drug daptomycin for treating heart infections and bacteremia, also known as bloodstream infection or ... -Scientist Live

Duke Says New Treatment Approved For Staph Infections  Aug 24, 2006
DURHAM -- According to Duke University Medical Center, researchers at the school have shown that an existing drug called daptomycin is effective in treating ... -Raleigh Chronicle

Staph faces a stronger opponent  Aug 17, 2006
The additional firepower, a prescription antibiotic called daptomycin, comes at a time when it's sorely needed, according to research published in this week's ... -News & Observer

Antibiotic-Resistant Staph Now a Major Threat  Aug 16, 2006
In the same issue of the journal, another study found that the antibiotic daptomycin is effective for treating bloodstream and heart infections caused by ... -Forbes

FDA OKs staph infection drug tested at Duke  Aug 17, 2006
Researchers at Duke conducted clinical tests of the drug -- called daptomycin -- for Cubist Pharmaceuticals, which manufactures it. ... -Bizjournals.com

Staph infections on rise  Aug 17, 2006
News of growing community-based infections came as scientists at Duke University reported in the same journal on daptomycin, a recently approved antibiotic ... -Newsday

The New England Journal of Medicine Publishes Results of Cubist's ...  Aug 17, 2006
...that the New England Journal of Medicine (NEJM) has published results from the company's landmark Phase 3 study of CUBICIN(R) (daptomycin for injection) at 6 mg ... -PharmaLive.com

Hospitals Report Increase in Drug-Resistant Staph Infections  Aug 17, 2006
A separate study in the same edition of the journal said that daptomycin, sold as Cubicin, appeared to work better than standard antibiotics against ... -Los Angeles Times

Duke in the News: Aug. 17, 2006  Aug 18, 2006
17 -- News of a growing drug-resistant bacterial strain came as scientists at Duke reported on daptomycin, a recently approved antibiotic capable of treating ... -Duke University

AUDIO SUMMARY  Aug 16, 2006
Featured are articles on daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, methicillin-resistant S. aureus ... -New England Journal of Medicine (subscription)

Cubist Pharmaceuticals Reports Second Quarter 2006 Results; Total ...  Jul 19, 2006
In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... -Genetic Engineering News

Novartis Generates Strong Sales and Earnings Growth in the First ...  Jul 17, 2006
Cubicin (daptomycin), an antibiotic for complicated skin and soft tissue infections (cSSTI), was launched in the UK, Germany and the Netherlands after EU ... -PharmaLive.com



Cubist Pharmaceuticals Reports First Quarter 2006 Results; Total ...  Apr 19, 2006
In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... - Genetic Engineering News





Cubist Pharmaceuticals Has Submitted Response to FDA Approvable ...  Mar 27, 2006
CBST) today announced that the Company has submitted to the Food & Drug Administration (FDA) an amendment to the sNDA for CUBICIN(R) (daptomycin for injection ... - Genetic Engineering News

FDA Issues Approvable Letter for CUBICIN sNDA; Conference Call ...  Mar 24, 2006
...today announced that it has received an Approvable Letter from the US Food & Drug Administration (FDA) for the sNDA for CUBICIN(R) (daptomycin for injection). ... - Genetic Engineering News

The Hospital Antibacterial Market Presents New Opportunities for ...  Mar 15, 2006
With the availability of several products active against MRSA and VRE (eg, linezolid (Pfizer's Zyvox), daptomycin (Cubist's Cubicin)), the most significant ... - Genetic Engineering News

Cubist boosted by FDA panel vote  Mar 7, 2006
The Anti-Infective Drugs Advisory Committee (AIDAC) voted that there was substantial evidence of safety and efficacy of Cubicin (daptomycin for injection) in ... - Pharmaceutical Business Review

Cubist Pharmaceuticals Stock Trading Halted Today; FDA Advisory ...  06 Mar 2006
US Food and Drug Administration (FDA) meets today to review and discuss the Supplemental New Drug Application (sNDA) for CUBICIN(R) (daptomycin for injection ... - Genetic Engineering News,

Cubist Pharmaceuticals Announces Posting of Briefing Documents for ...  Mar 3, 2006
...documents posted on line today by the FDA refer to the sNDA filed by Cubist on September 21, 2005 for an expanded label for CUBICIN(R)(daptomycin for injection ... - Genetic Engineering News,

Anti-Infective Drugs Advisory Committee  Mar 2, 2006
The committee will discuss new drug application (NDA) 21-572/S-008, Cubicin (daptomycin for injection 500 mg/vial), Sponsor Cubist Pharmaceuticals, for the ... - FDA.gov

Scientists re-engineer antibiotic to counter drug resistance  Feb 9, 2006
The product, tigecycline (Tygacil) joins the oxazolidinones, (Pfizer's linezolid) and lipopeptides (Cubist's daptomycin) in a small but growing arsenal against ... - DrugResearcher.com,

Cubist Pharmaceuticals to Present at Upcoming Investor Conferences ...  Feb 1, 2006
In the US, Cubist markets CUBICIN(R) (daptomycin for injection), the first antibiotic in a new class of antiinfectives called lipopeptides. ... - Genetic Engineering News,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional